Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats.

Abstract

Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P ≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P = 0.0042) or exebacase (P < 0.001) alone.

• Authors: Melissa J Karau, Suzannah M Schmidt-Malan, Qun Yan, Kerryl E Greenwood-Quaintance, Jayawant Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 63 Issue 10 (10 2019) ISSN: 1098-6596 [Electronic] United States
• PMID: 31358593 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: Copyright © 2019 American Society for Microbiology.

Chemical References

• Anti-Bacterial Agents
• exebacase
• Vancomycin
• Endopeptidases
• Daptomycin

Topics

• Animals
• Anti-Bacterial Agents (administration & dosage, therapeutic use)
• Daptomycin (administration & dosage, therapeutic use)
• Endopeptidases (administration & dosage, therapeutic use)
• Male
• Methicillin-Resistant Staphylococcus aureus (drug effects, pathogenicity)
• Osteomyelitis (drug therapy, microbiology)
• Rats
• Rats, Sprague-Dawley
• Vancomycin (therapeutic use)